Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
High Keratin 8/18 Ratio Predicts Aggressive Hepatocellular Cancer Phenotype.
Golob-Schwarzl N, Bettermann K, Mehta AK, Kessler SM, Unterluggauer J, Krassnig S, Kojima K, Chen X, Hoshida Y, Bardeesy NM, Müller H, Svendova V, Schimek MG, Diwoky C, Lipfert A, Mahajan V, Stumptner C, Thüringer A, Fröhlich LF, Stojakovic T, Nilsson KPR, Kolbe T, Rülicke T, Magin TM, Strnad P, Kiemer AK, Moriggl R, Haybaeck J. Golob-Schwarzl N, et al. Among authors: krassnig s. Transl Oncol. 2019 Feb;12(2):256-268. doi: 10.1016/j.tranon.2018.10.010. Epub 2018 Nov 12. Transl Oncol. 2019. PMID: 30439626 Free PMC article.
Separation of low and high grade colon and rectum carcinoma by eukaryotic translation initiation factors 1, 5 and 6.
Golob-Schwarzl N, Schweiger C, Koller C, Krassnig S, Gogg-Kamerer M, Gantenbein N, Toeglhofer AM, Wodlej C, Bergler H, Pertschy B, Uranitsch S, Holter M, El-Heliebi A, Fuchs J, Punschart A, Stiegler P, Keil M, Hoffmann J, Henderson D, Lehrach H, Reinhard C, Regenbrecht C, Schicho R, Fickert P, Lax S, Haybaeck J. Golob-Schwarzl N, et al. Among authors: krassnig s. Oncotarget. 2017 Sep 5;8(60):101224-101243. doi: 10.18632/oncotarget.20642. eCollection 2017 Nov 24. Oncotarget. 2017. PMID: 29254159 Free PMC article.
Influence of eukaryotic translation initiation factor 6 on non-small cell lung cancer development and progression.
Gantenbein N, Bernhart E, Anders I, Golob-Schwarzl N, Krassnig S, Wodlej C, Brcic L, Lindenmann J, Fink-Neuboeck N, Gollowitsch F, Stacher-Priehse E, Asslaber M, Gogg-Kamerer M, Rolff J, Hoffmann J, Silvestri A, Regenbrecht C, Reinhard C, Pehserl AM, Pichler M, Sokolova O, Naumann M, Mitterer V, Pertschy B, Bergler H, Popper H, Sattler W, Haybaeck J. Gantenbein N, et al. Among authors: krassnig s. Eur J Cancer. 2018 Sep;101:165-180. doi: 10.1016/j.ejca.2018.07.001. Epub 2018 Aug 1. Eur J Cancer. 2018. PMID: 30077122 Free article.
Pharmacologic IL-6Rα inhibition in cholangiocarcinoma promotes cancer cell growth and survival.
Kleinegger F, Hofer E, Wodlej C, Golob-Schwarzl N, Birkl-Toeglhofer AM, Stallinger A, Petzold J, Orlova A, Krassnig S, Reihs R, Niedrist T, Mangge H, Park YN, Thalhammer M, Aigelsreiter A, Lax S, Garbers C, Fickert P, Rose-John S, Moriggl R, Rinner B, Haybaeck J. Kleinegger F, et al. Among authors: krassnig s. Biochim Biophys Acta Mol Basis Dis. 2019 Feb 1;1865(2):308-321. doi: 10.1016/j.bbadis.2018.11.006. Epub 2018 Nov 9. Biochim Biophys Acta Mol Basis Dis. 2019. PMID: 30419338 Free article.
Corrigendum to High Keratin 8/18 Ratio Predicts Aggressive Hepatocellular Cancer Phenotype12 [Translational Oncology Volume 12, Issue 2, February 2019, Pages 256-268].
Golob-Schwarzl N, Bettermann K, Mehta AK, Kessler SM, Unterluggauer J, Krassnig S, Kojima K, Chen X, Hoshida Y, Bardeesy NM, Müller H, Svendova V, Schimek MG, Diwoky C, Lipfert A, Mahajan V, Stumptner C, Thüringer A, Fröhlich LF, Stojakovic T, Nilsson KPR, Kolbe T, Rülicke T, Magin TM, Strnad P, Kiemer AK, Moriggl R, Haybaeck J. Golob-Schwarzl N, et al. Among authors: krassnig s. Transl Oncol. 2020 Feb;13(2):490-492. doi: 10.1016/j.tranon.2019.08.001. Transl Oncol. 2020. PMID: 32081369 Free PMC article. No abstract available.
Correction: Separation of low and high grade colon and rectum carcinoma by eukaryotic translation initiation factors 1, 5 and 6.
Golob-Schwarzl N, Schweiger C, Koller C, Krassnig S, Gogg-Kamerer M, Gantenbein N, Toeglhofer AM, Wodlej C, Bergler H, Pertschy B, Uranitsch S, Holter M, El-Heliebi A, Fuchs J, Punschart A, Stiegler P, Keil M, Hoffmann J, Henderson D, Lehrach H, Reinhard C, Regenbrecht C, Schicho R, Fickert P, Lax S, Haybaeck J. Golob-Schwarzl N, et al. Among authors: krassnig s. Oncotarget. 2023 Feb 2;14:83-84. doi: 10.18632/oncotarget.28115. Oncotarget. 2023. PMID: 36745526 Free PMC article. No abstract available.
Clinically relevant glioblastoma patient-derived xenograft models to guide drug development and identify molecular signatures.
Alcaniz J, Winkler L, Dahlmann M, Becker M, Orthmann A, Haybaeck J, Krassnig S, Skofler C, Kratzsch T, Kuhn SA, Jödicke A, Linnebacher M, Fichtner I, Walther W, Hoffmann J. Alcaniz J, et al. Among authors: krassnig s. Front Oncol. 2023 Apr 11;13:1129627. doi: 10.3389/fonc.2023.1129627. eCollection 2023. Front Oncol. 2023. PMID: 37114125 Free PMC article.
Decreased eukaryotic initiation factors expression upon temozolomide treatment-potential novel implications for eIFs in glioma therapy.
Krassnig S, Leber SL, Orthmann A, Golob-Schwarzl N, Huber HJ, Wohlrab C, Skofler C, Pennauer M, Raicht A, Birkl-Toeglhofer AM, Naumann M, Mahdy-Ali K, von Campe G, Leoni M, Alcaniz J, Hoffmann J, Wälchli T, Weis S, Benesch M, Haybaeck J. Krassnig S, et al. J Neurooncol. 2023 Oct;165(1):91-100. doi: 10.1007/s11060-023-04451-y. Epub 2023 Oct 31. J Neurooncol. 2023. PMID: 37907716 Free PMC article.
23 results